Vesnarinone
Vesnarinone is a cardiotonic agent, mixed phosphodiesterase 3 inhibitor and ion-channel modifier that has modest, dose-dependent, positive inotropic activity, but minimal negative chronotropic activity. Vesnarinone improves ventricular performance most in patients with the worst degree of heart failure. (In Vitro) :Vesnarinone (60 and 100 μg/mL; 48 h) inhibits the cell growth in a dose-dependent manner.Vesnarinone (60 μg/mL; 48 h) induces G1 arrest and apoptosis.Vesnarinone (60 μg/mL; 0, 12, 24, and 48 h) treatment increases p21-mRNA expression and decreases p21 protein slightly. (In Vivo) :Vesnarinone (oral gavage; 300 mg/kg; once daily; 6 w) binds covalently to rat liver in vivo.
Product Specifications
CAS Number
81840-15-5
Product Name Alternative
RG-0210 | RG 0210 | Piteranometozine | Vesnarinone
Field of Research
Pharmacology & Drug Discovery
Purity
>98% (HPLC)
Solubility
DMSO : 16.67 mg/mL. 42.15 mM
Smiles
N1C (=O) CCc2cc (ccc12) N1CCN (CC1) C (=O) c1cc (c (cc1) OC) OC
Molecular Formula
C22H25N3O4
Molecular Weight
395.46
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
6-[4- (3,4-dimethoxybenzoyl) piperazin-1-yl]-3,4-dihydro-1H-quinolin-2-one
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
NHP2L1 (NHP2 Non-Histone Chromosome Protein 2-like 1, FA1, FA-1, NHPX, 15.5K, OTK27, SNU13, SSFA1, SPAG12, SNRNP15-5) (PE)
NHP2L1 (NHP2 Non-Histone Chromosome Protein 2-like 1, FA1, FA-1, NHPX, 15.5K, OTK27, SNU13, SSFA1, SPAG12, SNRNP15-5) (PE)